Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.7% on an annualized basis…
13 Analysts Have This To Say About Vertex Pharmaceuticals
Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 13 analysts in the past three months, showcasing a mix…
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC’s ‘Final Trades’
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having recent news and price changes.
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Arcturus’ Inhaled mRNA Therapeutic In Cystic Fibrosis Study Highlights Potential Amid Competitive Landscape: Analyst
Arcturus Therapeutics shared Phase 1 and Phase 1b trial results for ARCT-032, an inhaled mRNA therapeutic for cystic fibrosis, showing FEV1 improvements and safety .
Vertex To Present New Data Demonstrating Significant Benefits Of Treatment With TRIKAFTA At The ECFS 47th European Cystic Fibrosis Conference Held June 5-8, 2024
- Results from a randomized, placebo-controlled study of TRIKAFTA® in people with cystic fibrosis with rare, non-F508del CFTR mutations showed statistically significant and clinically meaningful improvements in the
$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 9.91% on an annualized basis…
This Is What Whales Are Betting On Vertex Pharmaceuticals
Whales with a lot of money to spend have taken a noticeably bullish stance on Vertex Pharmaceuticals. Looking…
Analyst Expectations For Vertex Pharmaceuticals’s Future
During the last three months, 10 analysts shared their evaluations of Vertex Pharmaceuticals (NASDAQ:VRTX), revealing diverse outlooks from…
Arcturus Therapeutics’ Early Cystic Fibrosis Trial Results Encouraging – Analyst Cautiously Optimistic
Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung function.